Clinical trials: AL Amyloidosis
Amyloidosis; Systemic, Amyloidosis Cardiac
Essen Amyloidosis Registry
The Essen Amyloidosis Registry (EAR) is a prospective, observational registry designed to collect comprehensive clinical data on patients diagnosed with systemic amyloidosis.
- Trial name
- EAR (NCT06887283)
- Where
- Germany
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Essen
Multiple Myeloma, Primary Amyloidosis
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden
The goal of this clinical research study is to learn whether higher doses of stem cells can help to decrease the symptoms that occur after melphalan.
- Trial name
- NCT00651937
- Testing
- Melphalan, Stem Cell Infusion, Questionnaires
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Systemic Amyloidosis, PET/MR
The Diagnostic Value of Hybrid PET/MR for Systemic Amyloidosis
Systemic amyloidosis is a multi-system disease caused by extracellular deposition of insoluble amyloid fibrils in various tissues and organs, leading to progressive organ dysfunction.
- Trial name
- NCT04006223
- Testing
- 11C-PIB or 18F-florbetapir PET/MR before biopsy and treatment, 11C-PIB or 18F-florbetapir PET/MR after treatment
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Light Chain (AL) Amyloidosis, Stage 3B
A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis
This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed stage 3B light chain (AL) amyloidosis.
- Trial name
- NCT04131309
- Testing
- Daratumumab, Bortezomib Injection, Dexamethasone oral tablet
- Where
- 5 sites in France, Greece and 2 more
- Volunteers
- 40 people
- Sponsor
- Stichting European Myeloma Network
Amyloid, Cardiac Amyloidosis
Amyloidosis Incidence in High-Risk Cardiac Device Patients
This single-practice prospective cohort study aims to enhance the diagnosis of cardiac amyloidosis in high-risk patients undergoing standard cardiac device implantation.
- Conditions
- Amyloid, Cardiac Amyloidosis, Amyloidosis Cardiac, Systemic Amyloidosis
- Trial name
- NCT06186167
- Testing
- Chest Wall Fat Tissue Collection
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Midwest Heart & Vascular Specialists
Amyloidosis
Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)
To evaluate the efficacy and safety of Vel-Dex therapy (bortezomib and dexamethasone) followed by autologous hematopoietic stem cell transplantation as an initial treatment in patients with newly diagnosed AL.
- Trial name
- NCT01273844
- Testing
- Bortezomib
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Zhi-Hong Liu, M.D.
Multiple Myeloma
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future.
- Trial name
- NCT00898235
- Testing
- clonality analysis, polymerase chain reaction, protein analysis
- Where
- United States
- Volunteers
- 10,000 people
- Sponsor
- Boston Medical Center
Light Chain (AL) Amyloidosis
A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis
A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV patients with AL amyloidosis.
- Trial name
- AFFIRM-AL (NCT04973137)
- Testing
- Birtamimab, Standard of Care Chemotherapy
- Where
- 110 sites in United States, Australia and 21 more
- Volunteers
- 208 people
- Sponsor
- Prothena Biosciences Ltd.
AL Amyloidosis
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.
- Trial name
- NCT04392960
- Testing
- [18F]Florbetaben
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Primary Amyloidosis of Light Chain Type
Pomalidomide and Dexamethasone (PDex) in AL Amyloidosis
The aim of the study is to evaluate the safety and efficacy of Pomalidomide and Dexamethasone in patients who did not achieve a complete response after initial treatment with both an alkylating agent (Melphalan or…
- Trial name
- NCT01510613
- Testing
- Pomalidomide and Dexamethasone
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cancer
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients
RATIONALE: Liposomal amphotericin B may be effective in controlling fever and granulocytopenia. It is not yet known which regimen of liposomal amphotericin B is more effective in treating cancer patients who have these…
- Trial name
- NCT00003938
- Testing
- liposomal amphotericin B
- Where
- 24 sites in Belgium, Czechia and 13 more
- Volunteers
- 115 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Systemic AL Amyloidosis
Rapid dFLC Response Predict CHR in AL Amyloidosis
Light chain amyloidosis (AL amyloidosis) is a rare plasma cell dyscrasia characterized by the deposition of insoluble amyloid fibrils in multiple organ systems.
- Trial name
- NCT06627309
- Testing
- Dara IV, Bortezomib (drug), Dexamethasone
- Where
- 8 sites in China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
Cardiac AL Amyloidosis
A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy
Systemic amyloidoses are rare diseases affecting approximately 1 in 100,000 persons each year. In systemic amyloidoses abnormal proteins deposit in bodily organs and severely impair their function, causing death if not treated…
- Trial name
- NCT03474458
- Testing
- Doxycycline, Standard of care therapy
- Where
- 8 sites in Canada, France and 6 more
- Volunteers
- 19 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
This phase I trial studies the side effects and the best dose of sunitinib malate in treating human immunodeficiency virus (HIV)-positive patients with cancer receiving antiretroviral therapy.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT00890747
- Testing
- sunitinib malate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
This clinical trial studies the side effects and best dose of giving fludarabine and total-body irradiation (TBI) together followed by a donor stem cell transplant and cyclosporine and mycophenolate mofetil in treating human…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00112593
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Fred Hutchinson Cancer Center
AL Amyloidosis
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
The purpose of this protocol is to generate a registry of Chinese patients with AL amyloidosis treated with subcutaneous/intravenous daratumumab alone or subcutaneous/intravenous daratumumab combined with chemotherapy.
- Trial name
- NCT05277493
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking Union Medical College Hospital
Multiple Myeloma
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of abnormal plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- MRD (NCT00679367)
- Testing
- dexamethasone, lenalidomide, melphalan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Boston Medical Center
Cancer
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain
RATIONALE: Ketamine hydrochloride may lessen neuropathic pain in patients with cancer. It is not yet known whether ketamine hydrochloride given together with the best pain management is more effective than a placebo given…
- Trial name
- NCT01316744
- Testing
- ketamine hydrochloride, pharmacogenomic studies, questionnaire administration
- Where
- 3 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University of Glasgow
Amyloidosis; Systemic
Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients
This is a single arm, open label study designed to evaluate the safety and efficacy of propylene glycol-free melphalan hydrochloride in patients with AL amyloidosis.
- Trial name
- NCT02994784
- Testing
- Propylene Glycol-Free Melphalan Hydrochloride
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Boston Medical Center
Amyloidosis, Immunoglobulin Light-chain
Cardiac Amyloidosis Registry Study
This registry is a observational, multi-center study designed to collect data and analyze it retrospectively on patients with cardiac amyloidosis who have been evaluated and treated at major amyloid centers across the US and…
- Trial name
- CARS (NCT05174338)
- Testing
- Registry
- Where
- 23 sites in United States, Canada
- Volunteers
- 5,000 people
- Sponsor
- Cedars-Sinai Medical Center